Summary:
DESIGNED FOR PATIENTS WITH HEAVY MENSTRUAL BLEEDING ASSOCIATED WITH UTERINE FIBROIDS
RANDOMIZED PHASE 3 STUDY
STUDY DRUG OBE2109
APPROXIMATE 85 WEEK STUDY
POSSIBLE ADD-BACK THERAPY WITH STUDY DRUG OBE2109
Qualified Participants Must:
• HAVE DIAGNOSIS OF UTERINE FIBROIDS IN ADDITION TO HEAVY MENSTRUAL PERIODS
•
BE WILLING TO PARTICIPATE IN COLLECTION PROCESS TO ASSESS HEAVY MENSTRUAL FLOW
•
BE PRE-MENOPAUSAL
•
NOT BE PLANNING A PREGNANCY WHILE ENROLLED IN THE TRIAL
•
NOT HAVE OSTEOPOROSIS
Qualified Participants May Receive:
STUDY DRUG
COMPREHENSIVE MEDICAL CARE
STIPEND FOR TIME AND TRAVEL
COPIES OF ALL LABWORK REQUESTED